PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

• Status: Recruiting
• Trial end date: 2024-01-30

Summary

This is a phase 1/2 study of a drug called Ixazomib in combination with cytotoxic chemotherapy consisting of Vincristine, Dexamethasone, Asparaginase, and Doxorubicin (VXLD).

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Therapeutic Advances in Childhood Leukemia Consortium
• Collaborators: Children's Hospital Los Angeles; Takeda
• Treatments: Asparaginase; BB 1101; Dexamethasone; Dexamethasone acetate; Doxorubicin; Glycine; Ixazomib; Liposomal doxorubicin; Vincristine